| Literature DB >> 24650884 |
Mustafa Raoof1, Stuart J Corr2, Cihui Zhu1, Brandon T Cisneros2, Warna D Kaluarachchi1, Sophia Phounsavath2, Lon J Wilson3, Steven A Curley4.
Abstract
Hepatocellular carcinoma (HCC) is one of the most lethal and chemo-refractory cancers, clearly, alternative treatment strategies are needed. We utilized 10nm gold nanoparticles as a scaffold to synthesize nanoconjugates bearing a targeting antibody (cetuximab, C225) and gemcitabine. Loading efficiency of gemcitabine on the gold nanoconjugates was 30%. Targeted gold nanoconjugates in combination with RF were selectively cytotoxic to EGFR expressing Hep3B and SNU449 cells when compared to isotype particles with/without RF (P<0.05). In animal experiments, targeted gold nanoconjugates halted the growth of subcutaneous Hep3B xenografts in combination with RF exposure (P<0.05). These xenografts also demonstrated increased apoptosis, necrosis and decreased proliferation compared to controls. Normal tissues were unharmed. We have demonstrated that non-invasive RF-induced hyperthermia when combined with targeted delivery of gemcitabine is more effective and safe at dosages ~275-fold lower than the current clinically-delivered systemic dose of gemcitabine. FROM THE CLINICAL EDITOR: In a model of hepatocellular carcinoma, the authors demonstrate that non-invasive RF-induced hyperthermia applied with cetuximab targeted delivery of Au NP-gemcitabine conjugate is more effective and safe at dosages ~ 275-fold lower than the current clinically-used systemic dose of gemcitabine.Entities:
Keywords: Gemcitabine; Hepatocellular; Hyperthermia; Nanoparticle; Radiofrequency
Mesh:
Substances:
Year: 2014 PMID: 24650884 PMCID: PMC4349335 DOI: 10.1016/j.nano.2014.03.004
Source DB: PubMed Journal: Nanomedicine ISSN: 1549-9634 Impact factor: 5.307